Decagon Asset Management’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-242,436
Closed -$17.5M 82
2025
Q4
$17.5M Buy
+242,436
New +$15.7M 6.72% 6

Other funds holding RNAM

Decagon Asset Management's RNAM Position: Q1 2026 in Review

Decagon Asset Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 242,436 shares — an estimated $17.5M sold.

Decagon Asset Management first reported a position in RNAM in Q4 2025 and held it in 1 quarter. The position peaked at $17.5M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Decagon Asset Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Decagon Asset Management sold 242,436 Avidity Biosciences shares in Q1 2026, an estimated $17.5M.
  • Decagon Asset Management first reported a position in Avidity Biosciences in Q4 2025 and held it in 1 quarter.
  • Decagon Asset Management's Avidity Biosciences position peaked at $17.5M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Decagon Asset Management's 13F filing for Q1 2026, filed 15 May 2026.